Results 251 to 260 of about 216,066 (333)

CHARMM-GUI Hybrid ML/MM Builder for Hybrid Machine Learning and Molecular Mechanical Modeling and Simulations. [PDF]

J Chem Inf Model
Szczepaniak F, Suh D, Im W.
europepmc   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, Volume 183, Issue 7, Page 1364-1389, April 2026.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Clinical and Functional Characterization of PDE1A as a Wnt/<b>β</b>-Catenin-Linked Biomarker of Progression and Platinum Resistance in Epithelial Ovarian Cancer. [PDF]

Oncol Res
Han GH, Yun H, Chung JY, Kim JH, Cho H.
europepmc   +1 more source

Glycoprotein Proteinase in Agkistrodon bilineatus Venom [PDF]

, 1980
Johnson, Bob D., Ruff, John D., Sifford, Dewey H.   +2 more
core   +2 more sources

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

British Journal of Pharmacology, Volume 183, Issue 7, Page 1313-1340, April 2026.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang, Sijia Zhu, Na Xing, Zhen Zhou, Jiayi Chen, Tianen Si, Mingrui Li, Lin Jia, Yousef Rastegar‐Kashkooli, Tom J. Wang, Wei Zhu, Jing Li, Chao Jiang, Junmin Wang, Moxin Wu, Xiaoping Yin, Weidong Zang, Jian Wang, Songxue Su   +18 more
wiley   +1 more source

Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) - a prospective cohort study. [PDF]

BMC Pulm Med
Kam THH, Kam KKH, Wong MKL, Yan BPY, Tan G.   +4 more
europepmc   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

International Journal of Dermatology, Volume 65, Issue 4, Page 706-723, April 2026.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska, Isha Gandhi, Robert Adler, Deena Fayyad, Perya Bhagchandani, Shabnam Afzal, Waleed Adawi, Shivani Patel, Shawn G. Kwatra   +8 more
wiley   +1 more source

AMMONIA PLUS ANOTHER FACTOR ARE NECESSARY FOR DIFFERENTIATION IN SUBMERGED CLUMPS OF DICTYOSTELIUM [PDF]

, 1979
David, Charles N., Sternfeld, John
core  

Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 4, Page 610-616, April 2026.
We assessed four different doses of ME3183, a novel phosphodiesterase 4 inhibitor, and placebo in 132 patients with moderate to severe plaque psoriasis. At Week 16, more patients receiving ME3183 achieved ≥75% reduction in baseline Psoriasis Area and Severity Index scores than those receiving placebo, with no new safety concerns.
Kim A. Papp, April W. Armstrong, Tomokazu Koresawa, Kazunari Otake, Masayuki Hirata, Akiko Kano   +5 more
wiley   +1 more source

Intercellular diffusion of cyclic nucleotides followed by gap junction closure restarts meiosis in mouse preovulatory follicles. [PDF]

Proc Natl Acad Sci U S A
Nakashima IF, Zhong H, Nikolaev VO, Owen CM, Yee SP, Jaffe LA, Egbert JR.   +6 more
europepmc   +1 more source